MBX vs SPTX
MBX: A clinical-stage biopharmaceutical company leveraging a proprietary platform to optimize drug candidate properties and develop therapies across multiple indications. SPTX: Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics using its proprietary drug development platform.
Side-by-side fundamentals
| Metric | MBX | SPTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $58.30 | $21.30 | |
| Market cap as of 2026-07-23 | $2.9B | $1.1B | |
| PEG as of 2026-07-23 | -63.85 | n/a | |
| ROE as of 2026-07-23 | -24.5% | -24.2% | SPTX higher |
| ROA as of 2026-07-23 | -23.6% | -22.6% | SPTX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Beta as of 2026-07-23 | 1.55 | -1.38 | |
| 1-year return as of 2026-07-22 close | +394.5% | +5.8% | MBX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.